Identification of a novel O allele with c.777C & gt;G on an ABO*O.01.02 background
Transfusion. 2024 Mar 12. doi: 10.1111/trf.17785. Online ahead of print.NO ABSTRACTPMID:38469947 | DOI:10.1111/trf.17785 (Source: Transfusion)
Source: Transfusion - March 12, 2024 Category: Hematology Authors: Lin-Nan Shao Yi-Cheng Yang Yue-Xin Xia Chun-Xiang Li Shi-Hang Zhou Source Type: research
Tranexamic acid in trauma: After 3 hours from injury, when is it safe and effective to use again?
Transfusion. 2024 Mar 10. doi: 10.1111/trf.17779. Online ahead of print.ABSTRACTTranexamic acid (TXA) has proven mortality benefit if used early after traumatic injury, likely related to a combination of bleeding reduction and other non-bleeding effects. If TXA is given more than 3 h after traumatic injury, there is a significant and paradoxical increased risk of death due to bleeding. TXA has level 1 evidence for use as a bleeding reduction agent in isolated orthopedic operations, but in polytrauma patients undergoing orthopedic operations, it is not clear if and when TXA is safe or effective once outside the 3-h window o...
Source: Transfusion - March 10, 2024 Category: Hematology Authors: Christopher D Barrett Matthew D Neal Jonathan G Schoenecker Robert L Medcalf Paul S Myles Source Type: research
Tranexamic acid in trauma: After 3 hours from injury, when is it safe and effective to use again?
Transfusion. 2024 Mar 10. doi: 10.1111/trf.17779. Online ahead of print.ABSTRACTTranexamic acid (TXA) has proven mortality benefit if used early after traumatic injury, likely related to a combination of bleeding reduction and other non-bleeding effects. If TXA is given more than 3 h after traumatic injury, there is a significant and paradoxical increased risk of death due to bleeding. TXA has level 1 evidence for use as a bleeding reduction agent in isolated orthopedic operations, but in polytrauma patients undergoing orthopedic operations, it is not clear if and when TXA is safe or effective once outside the 3-h window o...
Source: Transfusion - March 10, 2024 Category: Hematology Authors: Christopher D Barrett Matthew D Neal Jonathan G Schoenecker Robert L Medcalf Paul S Myles Source Type: research
Tranexamic acid in trauma: After 3 hours from injury, when is it safe and effective to use again?
Transfusion. 2024 Mar 10. doi: 10.1111/trf.17779. Online ahead of print.ABSTRACTTranexamic acid (TXA) has proven mortality benefit if used early after traumatic injury, likely related to a combination of bleeding reduction and other non-bleeding effects. If TXA is given more than 3 h after traumatic injury, there is a significant and paradoxical increased risk of death due to bleeding. TXA has level 1 evidence for use as a bleeding reduction agent in isolated orthopedic operations, but in polytrauma patients undergoing orthopedic operations, it is not clear if and when TXA is safe or effective once outside the 3-h window o...
Source: Transfusion - March 10, 2024 Category: Hematology Authors: Christopher D Barrett Matthew D Neal Jonathan G Schoenecker Robert L Medcalf Paul S Myles Source Type: research
Comparable bacterial growth in platelet concentrates suspended in plasma and platelet additive solution and improved detection of bacterial contamination using a new generation automated culture system
DISCUSSION: Comparable bacterial detection was observed in plasma-PC and PAS-PC with PC sampling performed at 36-h post blood collection. PC sampling at ≤36 h could result in faster detection of facultative pathogenic organisms with the VIRTUO system and improved PC safety.PMID:38456520 | DOI:10.1111/trf.17772 (Source: Transfusion)
Source: Transfusion - March 8, 2024 Category: Hematology Authors: Yuntong Kou Dilini Kumaran Anita Howell Sandra Ramirez-Arcos Source Type: research
Comparable bacterial growth in platelet concentrates suspended in plasma and platelet additive solution and improved detection of bacterial contamination using a new generation automated culture system
DISCUSSION: Comparable bacterial detection was observed in plasma-PC and PAS-PC with PC sampling performed at 36-h post blood collection. PC sampling at ≤36 h could result in faster detection of facultative pathogenic organisms with the VIRTUO system and improved PC safety.PMID:38456520 | DOI:10.1111/trf.17772 (Source: Transfusion)
Source: Transfusion - March 8, 2024 Category: Hematology Authors: Yuntong Kou Dilini Kumaran Anita Howell Sandra Ramirez-Arcos Source Type: research
Identification of a novel A allele with a nucleotide deletion c.198delG in the ABO gene associated with A < sub > el < /sub > phenotype
Transfusion. 2024 Mar 6. doi: 10.1111/trf.17753. Online ahead of print.NO ABSTRACTPMID:38445770 | DOI:10.1111/trf.17753 (Source: Transfusion)
Source: Transfusion - March 6, 2024 Category: Hematology Authors: Haixiao Zheng Chan Peng Min Wang Qinhan Hong Lin Hua Source Type: research
Identification of a novel A allele with a nucleotide deletion c.198delG in the ABO gene associated with A < sub > el < /sub > phenotype
Transfusion. 2024 Mar 6. doi: 10.1111/trf.17753. Online ahead of print.NO ABSTRACTPMID:38445770 | DOI:10.1111/trf.17753 (Source: Transfusion)
Source: Transfusion - March 6, 2024 Category: Hematology Authors: Haixiao Zheng Chan Peng Min Wang Qinhan Hong Lin Hua Source Type: research
Identification of a novel A allele with a nucleotide deletion c.198delG in the ABO gene associated with A < sub > el < /sub > phenotype
Transfusion. 2024 Mar 6. doi: 10.1111/trf.17753. Online ahead of print.NO ABSTRACTPMID:38445770 | DOI:10.1111/trf.17753 (Source: Transfusion)
Source: Transfusion - March 6, 2024 Category: Hematology Authors: Haixiao Zheng Chan Peng Min Wang Qinhan Hong Lin Hua Source Type: research
The first two years of the use of low titer group O whole blood during French Military overseas operations: A retrospective study
CONCLUSION: LTOWB is transfused by the FMMS during overseas operations from the tactical MEDEVAC until Role 2 care. Deployment of LTOWB by the FMMS enables an early high-ratio plasma/RBC transfusion and an early platelet transfusion for combat casualties.PMID:38441209 | DOI:10.1111/trf.17776 (Source: Transfusion)
Source: Transfusion - March 5, 2024 Category: Hematology Authors: Jean-Cl ément Riff Olivier Duranteau Sylvain Ausset Pierre Pasquier Estelle Fleuriot Vanina Corominas Mathieu Boutonnet Source Type: research
Analyzing and modeling massive transfusion strategies and the role of fibrinogen-How much is the patient actually receiving?
DISCUSSION: Differences observed between modeled transfusion strategies provide key insights into potential opportunities to provide patients with precision transfusion strategy.PMID:38433522 | DOI:10.1111/trf.17774 (Source: Transfusion)
Source: Transfusion - March 4, 2024 Category: Hematology Authors: Nadia M Keltner Melissa M Cushing Thorsten Haas Philip C Spinella Source Type: research
Analyzing and modeling massive transfusion strategies and the role of fibrinogen-How much is the patient actually receiving?
DISCUSSION: Differences observed between modeled transfusion strategies provide key insights into potential opportunities to provide patients with precision transfusion strategy.PMID:38433522 | DOI:10.1111/trf.17774 (Source: Transfusion)
Source: Transfusion - March 4, 2024 Category: Hematology Authors: Nadia M Keltner Melissa M Cushing Thorsten Haas Philip C Spinella Source Type: research
Successful treatment of severe passenger lymphocyte syndrome with efgartigimod synergy
DISCUSSION: The synergistic effect of efgartigimod with eltrombopag and romiplostim most likely resolved the patient's thrombocytopenia. This case represents a novel use of efgartigimod in the treatment of passenger lymphocyte syndrome following liver transplant.PMID:38425280 | DOI:10.1111/trf.17748 (Source: Transfusion)
Source: Transfusion - March 1, 2024 Category: Hematology Authors: R Christopher Chase Andree H Koop Marwan Shaikh Robin J Imperial Denise M Harnois Nicole M Loo Jennifer J O'Brien Source Type: research
Successful treatment of severe passenger lymphocyte syndrome with efgartigimod synergy
DISCUSSION: The synergistic effect of efgartigimod with eltrombopag and romiplostim most likely resolved the patient's thrombocytopenia. This case represents a novel use of efgartigimod in the treatment of passenger lymphocyte syndrome following liver transplant.PMID:38425280 | DOI:10.1111/trf.17748 (Source: Transfusion)
Source: Transfusion - March 1, 2024 Category: Hematology Authors: R Christopher Chase Andree H Koop Marwan Shaikh Robin J Imperial Denise M Harnois Nicole M Loo Jennifer J O'Brien Source Type: research
Successful treatment of severe passenger lymphocyte syndrome with efgartigimod synergy
DISCUSSION: The synergistic effect of efgartigimod with eltrombopag and romiplostim most likely resolved the patient's thrombocytopenia. This case represents a novel use of efgartigimod in the treatment of passenger lymphocyte syndrome following liver transplant.PMID:38425280 | DOI:10.1111/trf.17748 (Source: Transfusion)
Source: Transfusion - March 1, 2024 Category: Hematology Authors: R Christopher Chase Andree H Koop Marwan Shaikh Robin J Imperial Denise M Harnois Nicole M Loo Jennifer J O'Brien Source Type: research
